Literature DB >> 18430890

Synthesis and characterization of mRNA cap analogs containing phosphorothioate substitutions that bind tightly to eIF4E and are resistant to the decapping pyrophosphatase DcpS.

Joanna Kowalska1, Magdalena Lewdorowicz, Joanna Zuberek, Ewa Grudzien-Nogalska, Elzbieta Bojarska, Janusz Stepinski, Robert E Rhoads, Edward Darzynkiewicz, Richard E Davis, Jacek Jemielity.   

Abstract

Analogs of the mRNA cap are widely employed to study processes involved in mRNA metabolism as well as being useful in biotechnology and medicinal applications. Here we describe synthesis of six dinucleotide cap analogs bearing a single phosphorothioate modification at either the alpha, beta, or gamma position of the 5',5'-triphosphate chain. Three of them were also modified with methyl groups at the 2'-O position of 7-methylguanosine to produce anti-reverse cap analogs (ARCAs). Due to the presence of stereogenic P centers in the phosphorothioate moieties, each analog was obtained as a mixture of two diastereomers, D1 and D2. The mixtures were resolved by RP HPLC, providing 12 different compounds. Fluorescence quenching experiments were employed to determine the association constant (K(AS)) for complexes of the new analogs with eIF4E. We found that phosphorothioate modifications generally stabilized the complex between eIF4E and the cap analog. The most strongly bound phosphorothioate analog (the D1 isomer of the beta-substituted analog m(7)Gpp(S)pG) was characterized by a K(AS) that was more than fourfold higher than that of its unmodified counterpart (m(7)GpppG). All analogs modified in the gamma position were resistant to hydrolysis by the scavenger decapping pyrophosphatase DcpS from both human and Caenorhabditis elegans sources. The absolute configurations of the diastereomers D1 and D2 of analogs modified at the alpha position (i.e., m(7)Gppp(S)G and m(2) (7,2'-O )Gppp(S)G) were established as S(P) and R(P) , respectively, using enzymatic digestion and correlation with the S(P) and R(P) diastereomers of guanosine 5'-O-(1-thiodiphosphate) (GDPalphaS). The analogs resistant to DcpS act as potent inhibitors of in vitro protein synthesis in rabbit reticulocyte lysates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18430890      PMCID: PMC2390807          DOI: 10.1261/rna.990208

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  33 in total

1.  Synthesis and application of a chain-terminating dinucleotide mRNA cap analog.

Authors:  Zheng-Hong Peng; Vivek Sharma; Scott F Singleton; Paul D Gershon
Journal:  Org Lett       Date:  2002-01-24       Impact factor: 6.005

2.  Human Dcp2: a catalytically active mRNA decapping enzyme located in specific cytoplasmic structures.

Authors:  Erwin van Dijk; Nicolas Cougot; Sylke Meyer; Sylvie Babajko; Elmar Wahle; Bertrand Séraphin
Journal:  EMBO J       Date:  2002-12-16       Impact factor: 11.598

Review 3.  eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation.

Authors:  A C Gingras; B Raught; N Sonenberg
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

4.  Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl(3'-O-methyl)GpppG and 7-methyl (3'-deoxy)GpppG.

Authors:  J Stepinski; C Waddell; R Stolarski; E Darzynkiewicz; R E Rhoads
Journal:  RNA       Date:  2001-10       Impact factor: 4.942

5.  Biophysical studies of eIF4E cap-binding protein: recognition of mRNA 5' cap structure and synthetic fragments of eIF4G and 4E-BP1 proteins.

Authors:  Anna Niedzwiecka; Joseph Marcotrigiano; Janusz Stepinski; Marzena Jankowska-Anyszka; Aleksandra Wyslouch-Cieszynska; Michal Dadlez; Anne-Claude Gingras; Pawel Mak; Edward Darzynkiewicz; Nahum Sonenberg; Stephen K Burley; Ryszard Stolarski
Journal:  J Mol Biol       Date:  2002-06-07       Impact factor: 5.469

6.  Novel "anti-reverse" cap analogs with superior translational properties.

Authors:  Jacek Jemielity; Tolvert Fowler; Joanna Zuberek; Janusz Stepinski; Magdalena Lewdorowicz; Anna Niedzwiecka; Ryszard Stolarski; Edward Darzynkiewicz; Robert E Rhoads
Journal:  RNA       Date:  2003-09       Impact factor: 4.942

7.  Insights into the structure, mechanism, and regulation of scavenger mRNA decapping activity.

Authors:  Meigang Gu; Carme Fabrega; Shin-Wu Liu; Hudan Liu; Megerditch Kiledjian; Christopher D Lima
Journal:  Mol Cell       Date:  2004-04-09       Impact factor: 17.970

8.  The hDcp2 protein is a mammalian mRNA decapping enzyme.

Authors:  Zuoren Wang; Xinfu Jiao; Anne Carr-Schmid; Megerditch Kiledjian
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-06       Impact factor: 11.205

9.  The scavenger mRNA decapping enzyme DcpS is a member of the HIT family of pyrophosphatases.

Authors:  Hudan Liu; Nancy D Rodgers; Xinfu Jiao; Megerditch Kiledjian
Journal:  EMBO J       Date:  2002-09-02       Impact factor: 11.598

Review 10.  Viral and cellular mRNA capping: past and prospects.

Authors:  Y Furuichi; A J Shatkin
Journal:  Adv Virus Res       Date:  2000       Impact factor: 9.937

View more
  37 in total

1.  Emerging therapeutics targeting mRNA translation.

Authors:  Abba Malina; John R Mills; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

2.  mRNAs biotinylated within the 5' cap and protected against decapping: new tools to capture RNA-protein complexes.

Authors:  Sylwia Bednarek; Vanesa Madan; Pawel J Sikorski; Ralf Bartenschlager; Joanna Kowalska; Jacek Jemielity
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-11-05       Impact factor: 6.237

3.  Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes.

Authors:  Joanna Kowalska; Anna Wypijewska del Nogal; Zbigniew M Darzynkiewicz; Janina Buck; Corina Nicola; Andreas N Kuhn; Maciej Lukaszewicz; Joanna Zuberek; Malwina Strenkowska; Marcin Ziemniak; Maciej Maciejczyk; Elzbieta Bojarska; Robert E Rhoads; Edward Darzynkiewicz; Ugur Sahin; Jacek Jemielity
Journal:  Nucleic Acids Res       Date:  2014-08-22       Impact factor: 16.971

4.  mRNA cap analogues substituted in the tetraphosphate chain with CX2: identification of O-to-CCl2 as the first bridging modification that confers resistance to decapping without impairing translation.

Authors:  Anna M Rydzik; Marcin Warminski; Pawel J Sikorski; Marek R Baranowski; Sylwia Walczak; Joanna Kowalska; Joanna Zuberek; Maciej Lukaszewicz; Elzbieta Nowak; Timothy D W Claridge; Edward Darzynkiewicz; Marcin Nowotny; Jacek Jemielity
Journal:  Nucleic Acids Res       Date:  2017-09-06       Impact factor: 16.971

5.  Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening.

Authors:  Alexandra G Orlandini von Niessen; Marco A Poleganov; Corina Rechner; Arianne Plaschke; Lena M Kranz; Stephanie Fesser; Mustafa Diken; Martin Löwer; Britta Vallazza; Tim Beissert; Valesca Bukur; Andreas N Kuhn; Özlem Türeci; Ugur Sahin
Journal:  Mol Ther       Date:  2018-12-18       Impact factor: 11.454

Review 6.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

7.  Translation, stability, and resistance to decapping of mRNAs containing caps substituted in the triphosphate chain with BH3, Se, and NH.

Authors:  Wei Su; Sergey Slepenkov; Ewa Grudzien-Nogalska; Joanna Kowalska; Marta Kulis; Joanna Zuberek; Maciej Lukaszewicz; Edward Darzynkiewicz; Jacek Jemielity; Robert E Rhoads
Journal:  RNA       Date:  2011-03-29       Impact factor: 4.942

8.  β,γ-CHF- and β,γ-CHCl-dGTP diastereomers: synthesis, discrete 31P NMR signatures, and absolute configurations of new stereochemical probes for DNA polymerases.

Authors:  Yue Wu; Valeria M Zakharova; Boris A Kashemirov; Myron F Goodman; Vinod K Batra; Samuel H Wilson; Charles E McKenna
Journal:  J Am Chem Soc       Date:  2012-05-18       Impact factor: 15.419

Review 9.  Viral and Synthetic RNA Vector Technologies and Applications.

Authors:  Juliane W Schott; Michael Morgan; Melanie Galla; Axel Schambach
Journal:  Mol Ther       Date:  2016-07-05       Impact factor: 11.454

10.  mRNAs containing the histone 3' stem-loop are degraded primarily by decapping mediated by oligouridylation of the 3' end.

Authors:  Wei Su; Sergey V Slepenkov; Michael K Slevin; Shawn M Lyons; Marcin Ziemniak; Joanna Kowalska; Edward Darzynkiewicz; Jacek Jemielity; William F Marzluff; Robert E Rhoads
Journal:  RNA       Date:  2012-11-27       Impact factor: 4.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.